The Federal Trade Commission today announced that it has filed civil contempt charges against Lane Labs, Inc., for violating FTC orders entered in 2000 requiring the company to have competent and reliable scientific evidence to substantiate ad claims and prohibiting deceptive claims about tests, studies, or research.
The FTC alleged that Lane Labs violated the order against them by claiming that Fertil Male, a dietary supplement, enhances male fertility.
The FTC also alleged that Lane Labs violated the FTC orders by claiming that AdvaCAL, a calcium supplement also sold as AAACa, is superior to other calcium products and on par with or superior to prescription drugs used to fight osteoporosis.
The company and its principals entered into the orders in 2000 to settle FTC charges that they made unsubstantiated claims about the efficacy of two products -- BeneFin and SkinAnswer -- in the prevention, treatment, and cure of cancer.
According to the FTC, the defendants' claims that Fertil Male improves male fertility are based on flawed scientific studies. The Commission also charged that the defendants have made numerous unsubstantiated claims about the benefits of AdvaCAL, and misrepresented test results and studies involving AdvaCAL and other calcium products.
The FTC charged that the studies do not support the claims, and that the studies of AdvaCAL are "fatally flawed."
The FTC charged that the defendants do not have competent and reliable scientific evidence to back up their claims and have misrepresented the results of scientific research when claiming:
• Fertil Male improves male fertility;
• AdvaCAL is more absorbable than other types of calcium;
• AdvaCAL is superior to other calcium or prescription drug products at building bone or increasing bone mineral density; and
• AdvaCAL is superior to other calcium products in preventing or reducing the risk of fractures.
The products are sold on the Internet, in catalogs, by direct mail, on infomercials, and at retail. A one-month supply of Fertil Male costs $34.95 at retail. A 25-day supply of AdvaCAL costs $39.95 at retail.
The FTC is seeking to recover all revenues stemming from the defendants' order violations.
